

**Minutes CHAP Meeting
May 11 & 12, 2005
Vancouver, Canada**

Members Present: Marie Courchesne, Deborah Kelly, Linda Akagi, Linda Sulz, Lizanne Béique, Domonic Khoo, Jinell Mah Ming, Alice Tseng, Michelle Foisy, Christine Hughes, Jeff Kapler, Deborah Yoong, Lyne Labbé, Nancy Sheehan

Minutes recorded by: Michelle Foisy
Minutes from 2004 meeting were approved by the group.

1. Group members/functions:

Meeting Chair: Marie Courchense
New Chair 2005-06: Deborah Kelly
New Secretary 2005-06: Michelle Foisy

Chair responsibilities:

- 1) Oversee projects
- 2) Funding for meetings
- 3) Agenda for CHAP meetings

Secretary Responsibilities:

- 1) Assist Chair with meeting agendas
- 2) Record minutes
- 3) Support Chair
- 4) Coordinate Newsletter

Group Members/Funding:

There are 25 active members in CHAP. BMS generously funded the meeting this year. Any remaining funds will be dedicated towards various research projects, ethics submission, and funding for future CHAP meetings.

ACTION: The Chair is to revisit membership.

2. Newsletter discussion

It was decided that the newsletter should be resurrected 3 times yearly. To share the workload, members have volunteered to coordinate various sections. The secretary will compile all information and disseminate the newsletter via e-mail.

- 1) Case forum- members are invited to submit an interesting learning case (Secretary- Michelle)
- 2) Report on projects (Chair- Deb)
- 3) Notification of upcoming conferences, dates, locations, and abstract deadlines (Linda Sulz)
- 4) Publication highlights (Christine Hughes)
- 5) Compilation of Correspondence (Jinell Mah Ming)
- 6) Website maintenance (update directory/ new members/ highlight posted presentations) (Alice Tseng)

ACTION: Please forward respective sections to the secretary by **September 15th, 2005**.

3. Update on 2004-05 Research:

Nancy Sheehan presented the progress with her project “The Effects of Aging on the Pharmacokinetics of Nelfinavir and its Metabolite”. Lyne Labbé, Ph.D. (University of Montreal) is the primary investigator. To minimize confounding variables, anticipated protocol changes include incorporating a pharmacogenetic analysis and reviewing bioequivalence data for the 250mg and 625mg formulations. There will be 2 consent forms (genetic and kinetic) with an explanation of the amendments. Ethics approval is underway and the project is funded by Pfizer.

Four sites are interested in participating: Edmonton, Ottawa, Montreal Chest and Halifax. In addition, Regina and Vancouver also expressed interest.

ACTION: Nancy to forward new protocol, forms and amendments to study sites. Nancy to provide copy of presentation slides to Alice for posting on the CHAP website.

4. Presentations:

- 1) Lyne Labbé gave an informative presentation on “Population PK/PD modeling of ARVs”
- 2) Christine Hughes provided a timely review of the 3rd European HIV Drug Resistance Workshop, Athens Greece 2005.
- 3) Mitra Montazeri, BMS Scientific Affairs, Medical Liaison for HIV provided an update on Atazanavir.
- 4) Alice Tseng reviewed drug interaction data presented at the Pharmacology Meeting in Quebec (satellite symposium).

For more information on other conference presentations visit www.hivpresentations.com and www.cfenet.ubc.ca (education, video, CAHR 2005) or <http://www.cfenet.ubc.ca/video.php?id=23&sid=33&cat=41>

ACTION: Presenters are to forward slides to Alice Tseng for posting on the CHAP website.

5. New Projects:

- 1) Lyne Labbé: HIV PK/PD cohort study
- 2) Christine Hughes: Experience with nucleotide/side backbones
- 3) Christine Hughes: Review of the ARVs in pregnancy study
- 4) Jinell Mah Ming: Kaletra in pregnancy- outcomes
- 5) Jinell Mah Ming: Medications used to treat drug side-effects
- 6) Jinell Mah Ming: ARVs and hypertension
- 7) Michelle Foisy: Tenofovir nephrotoxicity, bone toxicity
- 8) Lizanne Béique: Inhaled steroid and ritonavir interaction
- 9) Deborah Yoong (on behalf of St. Mike’s group): Qualitative study on access to patient drug information
- 10) Dominic Khoo: Use of contraception in women taking efavirenz
- 11) Marie Courchesne: Outcomes for atazanavir-induced hyperbilirubinemia

Two projects were chosen as CHAP 2005-06 initiatives- Nancy’s nelfinavir PK study and the St. Mike’s survey on drug information in patients.

Other studies might still be conducted by respective individuals and CHAP group members are welcome to participate in any of these studies. There must be at least 3 participating sites in order for the study to be considered a CHAP initiative. Some of the ethics costs may be paid by CHAP.

ACTION: Members listed above to forward a brief study description to Chair (Deb) by **June 15, 2005**. Deb will compile the list and circulate to CHAP members for potential participation in study. Each member is to inquire about institutional ethics reviews submission and costs.